

Fig. 1





Fig. 2



## Neutralization of TNF Cytotoxicity by Murine A2





FIG. 3







Fig. 6








Fig 8




pA2HG1apgpt



pA2HuKapgpt

Murine A2 ELISA with chimeric A2 competitor



Chimeric A2 ELISA with murine A2 competitor




FIG. 9

# Scatchard Analysis of I-125 mA2 and cA2 IgG





Fig. 10

Neutralization of TNF Cytotoxicity by Chimeric A2




FIG. 11

Neutralization of ELAM-1 Expression by Chimeric A2




FIG. 12

## Figure 13

# SEQUENCE OF HUMAN TNF

[illegible]

Figure 14





Figure 15

PEPTIDE SEQUENCE OF HUMAN TNF RECOGNIZED BY cA2

1 Val Arg Ser Ser Arg Thr Pro Ser Asp Lys Pro Val Ala His Val Val Ala Asn Pro  
10  
21 Gln Ala Glu Gly Gln Leu Gln Trp Leu Asn Arg Arg Ala Asn Ala Leu Leu Ala Asn Gly  
30  
41 Val Glu Leu Arg Asp Asn Gln Leu Val Val Pro Ser Glu Gly Leu Tyr Leu Ile  
50  
61 Gln Val Leu Phe Lys Gly Gln Gly Cys Pro Ser Thr His Val Leu Leu Thr His Thr Ile  
70  
81 Ser Arg Ile Ala Val Ser Tyr Gln Thr Lys Val Asn Leu Leu Ser Ala Ile Lys Ser Pro  
90  
101 Gln Arg Glu Thr Pro Gln Gly Ala Glu Ala Lys Pro Trp Tyr Glu Pro Ile Tyr Leu  
110  
121 Gly Gly Val Phe Gln Leu Glu Lys Gly Asp Arg Leu Ser Ala Glu Ile Asn Arg Pro Asp  
130  
141 Tyr Leu Asp Phe Ala Glu Ser Gly Gln Val Tyr Phe Gly Ile Ile Ala Leu  
150

Figure 16



07 943852

Figure 17A

## CA2 LIGHT CHAIN VARIABLE REGION SEQUENCE

GACATCTTGCTGACTCAGTCTCCAGCCATCCTGTCTGTGAGTCCAGGAGAAAGAGTCAGT  
AspIleLeuLeuThrGlnSerProAlaIleLeuSerValSerProGlyGluArgValSer

TTCTCCTGCCAGCGCCAGTCAGTTCGTTGGCTCAAGCATCCACTGGTATCAGCAAAGAACA  
PheSerCysArgAlaSerGlnPheValGlySerSerIleHisTrpTyrGlnGlnArgThr

AATGGTTCTCCAAGGCTTCTCATAAAGTATGCTTCTGAGTCTATGTCTGGGATCCCTTCC  
AsnGlySerProArgLeuLeuIleLysTyrAlaSerGluSerMetSerGlyIleProSer

AGGTTTAGTGGCAGTGGATCAGGGACAGATTTTACTCTTAGCATCAACACTGTGCAGTCT  
ArgPheSerGlySerGlySerGlyThrAspPheThrLeuSerIleAsnThrValGluSer

GAAGATATTGCAGATTATTACTGTCAACAAAGTCATAGCTGCCCATTCACGTTCCGCTCG  
GluAspIleAlaAspTyrTyrCysGlnGlnSerHisSerTrpProPheThrPheGlySer

GGGACAAATTTCGAAGTAAAA  
GlyThrAsnLeuGluValLys

CAACTCAACCTTGACGACTCTCCACGACGCTTCGTGCAACCTGCAGGATCCATCAAACTC  
GluValLysLeuGluGluSerGlyGlyGlyLeuValGlnProGlyGlySerMetLysLeu

TCCTGTGTTGCCTCTGGATTCATTTTCAGTAACCACTGGATGAACTGGGTCCGCCAGTCT  
SerCysValAlaSerGlyPheIlePheSerAsnHisTrpMetAsnTrpValArgGlnSer

CCAGAGAAGGGGCTTGAGTGGGTGCTGAAATTAGATCAAAATCTATTAATTCTGCAACA  
ProGluLysGlyLeuGluTrpValAlaGluIleArgSerLysSerIleAsnSerAlaThr

CATTATGCGGAGTCTGTGAAAGGGAGGTTCCACCATCTCAAGAGATGATTCCAAAAGTGCT  
HisTyrAlaGluSerValLysGlyArgPheThrIleSerArgAspAspSerLysSerAla

GTCTACCTGCAAATGACCGACTTAAGAACTGAAGAGACTGGCGTTTATTACTGTTCAGG  
ValTyrLeuGlnMetThrAspLeuArgThrGluAspThrGlyValTyrTyrCysSerArg

AATTACTACGGTAGTACCTACGACTACTGGGGCCAAGGCACCACTCTCACAGTCTCC  
AsnTyrTyrGlySerThrTyrAspTyrTrpGlyGlnGlyThrThrLeuThrValSer

Figure 17B

## anti-TNF Trial

EMS




FIG-18

# anti-TNF Trial

## Pain





FIG. 19

## anti-TNF Trial

## Ritchie Articular Index



# anti-TNF Trial

## Swollen Joints




FIG 21

## anti-TNF Trial

## CRP




FIG. 22

## anti-TNF Trial

## ESR




FIG 23

## anti-TNF Trial

## Index of Disease Activity




FIG 24